{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:14Z","timestamp":1793730914567,"version":"4.6.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.kint.2021.03.019","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T21:43:46Z","timestamp":1617227026000},"page":"79-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone"],"prefix":"10.1016","volume":"100","author":[{"given":"Mark R.","family":"Hanudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gabayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Ganz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2021.03.019_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2021.03.019_bib2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/sj.ki.5000105","article-title":"Association of anemia with outcomes in men with moderate and severe chronic kidney disease","volume":"69","author":"Kovesdy","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.019_bib3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1440-1797.2008.01065.x","article-title":"Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease","volume":"14","author":"Thorp","year":"2009","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kint.2021.03.019_bib4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.34067\/KID.0000852020","article-title":"Anemia and incident end-stage renal disease","volume":"1","author":"Saraf","year":"2020","journal-title":"Kidney360"},{"key":"10.1016\/j.kint.2021.03.019_bib5","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000455166","article-title":"Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients","volume":"45","author":"Locatelli","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","article-title":"Regulation of erythropoiesis by hypoxia-inducible factors","volume":"27","author":"Haase","year":"2013","journal-title":"Blood Rev"},{"key":"10.1016\/j.kint.2021.03.019_bib8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.019_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000464476","article-title":"Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease","volume":"45","author":"Martin","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/ndt\/gfy055","article-title":"Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents","volume":"34","author":"Haase","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.019_bib11","doi-asserted-by":"crossref","unstructured":"Nangaku M, Farag YMK, deGoma E, et\u00a0al. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized phase 2 trials in Japanese patients [e-pub ahead of print]. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaa060. Accessed December 16, 2020.","DOI":"10.1093\/ndt\/gfaa060"},{"key":"10.1016\/j.kint.2021.03.019_bib12","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2021.03.019_bib13","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.kint.2021.03.019_bib14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2215\/CJN.05931108","article-title":"Hepcidin\u2014a potential novel biomarker for iron status in chronic kidney disease","volume":"4","author":"Zaritsky","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib15","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ki.2009.21","article-title":"Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease","volume":"75","author":"Ashby","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.019_bib16","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2215\/CJN.08161109","article-title":"Reduction of serum hepcidin by hemodialysis in pediatric and adult patients","volume":"5","author":"Zaritsky","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib17","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s11914-018-0492-2","article-title":"Non-renal-related mechanisms of FGF23 pathophysiology","volume":"16","author":"Hanudel","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.kint.2021.03.019_bib18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1053\/j.gastro.2013.12.031","article-title":"Hypoxia-inducible factors link iron homeostasis and erythropoiesis","volume":"146","author":"Shah","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2021.03.019_bib19","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1523-1755.2004.00847.x","article-title":"Pretreatment with EPO reduces the injury and dysfunction caused by ischemia\/reperfusion in the mouse kidney in\u00a0vivo","volume":"66","author":"Patel","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.019_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MNH.0b013e32831a9dde","article-title":"Erythropoietin and renoprotection","volume":"18","author":"Bahlmann","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2021.03.019_bib21","doi-asserted-by":"crossref","first-page":"F873","DOI":"10.1152\/ajprenal.00576.2013","article-title":"Remote conditioning or erythropoietin before surgery primes kidneys to clear ischemia-reperfusion-damaged cells: a renoprotective mechanism?","volume":"306","author":"Gardner","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2021.03.019_bib22","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.3390\/ijms21103453","article-title":"Erythropoietin ameliorates ischemia\/reperfusion-induced acute kidney injury via inflammasome suppression in mice","volume":"21","author":"Kwak","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2021.03.019_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12882-017-0438-4","article-title":"Erythropoiesis stimulating agents and reno-protection: a meta-analysis","volume":"18","author":"Elliott","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib24","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.019_bib25","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) study","volume":"18","author":"Fliser","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib26","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2021.03.019_bib27","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2215\/CJN.02110216","article-title":"Fibroblast growth factor 23 and risk of CKD progression in children","volume":"11","author":"Portale","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib28","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.03.019_bib29","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Gutierrez","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2021.03.019_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2215\/CJN.02110217","article-title":"FGF23 and left ventricular hypertrophy in children with CKD","volume":"13","author":"Mitsnefes","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib31","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13890","article-title":"Erythroferrone is not required for the glucoregulatory and hematologic effects of chronic erythropoietin treatment in mice","volume":"6","author":"Coffey","year":"2018","journal-title":"Physiol Rep"},{"key":"10.1016\/j.kint.2021.03.019_bib32","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.3324\/haematol.2017.181743","article-title":"Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease","volume":"103","author":"Hanudel","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.kint.2021.03.019_bib33","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.ekir.2019.08.010","article-title":"Erythropoietin and fibroblast growth factor 23 in autosomal dominant polycystic kidney disease patients","volume":"4","author":"Hanudel","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2021.03.019_bib34","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI31370","article-title":"Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)","volume":"117","author":"Peyssonnaux","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.03.019_bib35","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1128\/MCB.00723-12","article-title":"The hypoxia-inducible factor-C\/EBP\u03b1 axis controls ethanol-mediated hepcidin repression","volume":"32","author":"Anderson","year":"2012","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.kint.2021.03.019_bib36","doi-asserted-by":"crossref","first-page":"41163","DOI":"10.1074\/jbc.M202653200","article-title":"C\/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism: cross-talk between C\/EBP pathway and iron metabolism","volume":"277","author":"Courselaud","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2021.03.019_bib37","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1074\/jbc.M110.173096","article-title":"Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signaling and iron homeostasis","volume":"286","author":"Lakhal","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2021.03.019_bib38","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1074\/jbc.M413248200","article-title":"Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins","volume":"280","author":"McMahon","year":"2005","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2021.03.019_bib39","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood-2007-07-100677","article-title":"Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis","volume":"111","author":"Silvestri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.kint.2021.03.019_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007875","article-title":"Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors","volume":"4","author":"Volke","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2021.03.019_bib41","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.03.019_bib42","doi-asserted-by":"crossref","first-page":"20055","DOI":"10.1074\/jbc.272.32.20055","article-title":"Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1","volume":"272","author":"Rolfs","year":"1997","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2021.03.019_bib43","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood-2007-04-087593","article-title":"Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2\/4","volume":"110","author":"Lin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.kint.2021.03.019_bib44","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.24178","article-title":"Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice","volume":"53","author":"Ramos","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2021.03.019_bib45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1172\/JCI115652","article-title":"Age-dependent expression of the erythropoietin gene in rat liver and kidneys","volume":"89","author":"Eckardt","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.03.019_bib46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1152\/physrev.1992.72.2.449","article-title":"Erythropoietin: structure, control of production, and function","volume":"72","author":"Jelkmann","year":"1992","journal-title":"Physiol Rev"},{"key":"10.1016\/j.kint.2021.03.019_bib47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1292\/jvms.68.65","article-title":"Erythropoietin-producing cells in the liver of ICR-derived glomerulonephritis (ICGN) mice","volume":"68","author":"Yamaguchi-Yamada","year":"2006","journal-title":"J\u00a0Vet Med Sci"},{"key":"10.1016\/j.kint.2021.03.019_bib48","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1681\/ASN.2015050508","article-title":"Increased synthesis of liver erythropoietin with CKD","volume":"27","author":"de Seigneux","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1073\/pnas.0509459103","article-title":"Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production","volume":"103","author":"Safran","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2021.03.019_bib50","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD","volume":"21","author":"Bernhardt","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1192811","article-title":"Reactivation of hepatic EPO synthesis in mice after PHD loss","volume":"329","author":"Minamishima","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.kint.2021.03.019_bib52","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2012-04-423715","article-title":"Treatment of erythropoietin deficiency in mice with systemically administered siRNA","volume":"120","author":"Querbes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.kint.2021.03.019_bib53","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1182\/blood-2010-02-270322","article-title":"Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia","volume":"116","author":"Kapitsinou","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.kint.2021.03.019_bib54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12185-018-2531-2","article-title":"Deregulated iron metabolism in bone marrow from adenine-induced mouse model of chronic kidney disease","volume":"109","author":"Kimura","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.kint.2021.03.019_bib55","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","article-title":"Hypoxia-inducible factor-2\u03b1 mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice","volume":"140","author":"Taylor","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2021.03.019_bib56","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice","volume":"119","author":"Mastrogiannaki","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.03.019_bib57","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","article-title":"Systemic iron homeostasis","volume":"93","author":"Ganz","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.kint.2021.03.019_bib58","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.kint.2019.02.016","article-title":"Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis","volume":"96","author":"Schley","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.019_bib59","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ndt\/gfg021","article-title":"Haematocrit and the risk of developing end-stage renal disease","volume":"18","author":"Iseki","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.019_bib60","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1523-1755.2004.00863.x","article-title":"Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy","volume":"66","author":"Mohanram","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.019_bib61","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.semnephrol.2006.05.004","article-title":"Role of anemia in progression of chronic kidney disease","volume":"26","author":"Rossert","year":"2006","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib62","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1053\/j.ajkd.2015.01.008","article-title":"Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the Chronic Kidney Disease in Children (CKiD) cohort","volume":"65","author":"Warady","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.03.019_bib63","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000190270","article-title":"Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients","volume":"77","author":"Kuriyama","year":"1997","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2021.03.019_bib64","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1523-1755.2004.00797.x","article-title":"Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial","volume":"66","author":"Gouva","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.019_bib65","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.019_bib66","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.019_bib67","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000366025","article-title":"Erythropoiesis-stimulating agents (ESA) for preventing the progression of chronic kidney disease: a meta-analysis of 19 studies","volume":"40","author":"Covic","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib68","doi-asserted-by":"crossref","first-page":"F501","DOI":"10.1152\/ajprenal.00306.2017","article-title":"Effects of erythropoietin receptor activity on angiogenesis, tubular injury, and fibrosis in acute kidney injury: a \"U-shaped\" relationship","volume":"314","author":"Shi","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2021.03.019_bib69","doi-asserted-by":"crossref","first-page":"F14","DOI":"10.1152\/ajprenal.00323.2019","article-title":"JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors","volume":"318","author":"Wakashima","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2021.03.019_bib70","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1681\/ASN.2019060582","article-title":"Prolyl hydroxylase domain inhibitor protects against metabolic disorders and associated kidney disease in obese type 2 diabetic mice","volume":"31","author":"Sugahara","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib71","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.kint.2019.10.020","article-title":"Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage","volume":"97","author":"Ito","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.019_bib72","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.019_bib73","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/ndt\/gfp191","article-title":"High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.019_bib74","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.2215\/CJN.04290511","article-title":"Fibroblast growth factor 23 in patients undergoing peritoneal dialysis","volume":"6","author":"Isakova","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.019_bib75","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.019_bib76","doi-asserted-by":"crossref","first-page":"E1146","DOI":"10.1073\/pnas.1110905108","article-title":"Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice","volume":"108","author":"Farrow","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2021.03.019_bib77","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/boneres.2016.11","article-title":"The hypoxia-inducible factor-1alpha activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia","volume":"4","author":"Zhang","year":"2016","journal-title":"Bone Res"},{"key":"10.1016\/j.kint.2021.03.019_bib78","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.3324\/haematol.2017.167882","article-title":"Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow","volume":"102","author":"Clinkenbeard","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.kint.2021.03.019_bib79","doi-asserted-by":"crossref","first-page":"F132","DOI":"10.1152\/ajprenal.00081.2017","article-title":"Acute blood loss stimulates fibroblast growth factor 23 production","volume":"314","author":"Rabadi","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2021.03.019_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186979","article-title":"FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase","volume":"12","author":"Flamme","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2021.03.019_bib81","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.kint.2017.11.018","article-title":"Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury","volume":"93","author":"Toro","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.019_bib82","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00424-018-2171-7","article-title":"Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men","volume":"470","author":"Daryadel","year":"2018","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.kint.2021.03.019_bib83","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/ndt\/gfy189","article-title":"Effects of erythropoietin on fibroblast growth factor 23 in mice and humans","volume":"34","author":"Hanudel","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.019_bib84","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14434","article-title":"Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)","volume":"8","author":"Noonan","year":"2020","journal-title":"Physiol Rep"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821003549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821003549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:00:45Z","timestamp":1758762045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253821003549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0085253821003549"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2021.03.019","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}